Rocket Pharmaceuticals (RCKT) Cash & Equivalents (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Cash & Equivalents data on file, last reported at $144.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 189.9% year-over-year to $144.4 million; the trailing twelve-month figure through Mar 2026 stood at $144.4 million (up 189.9% YoY), and the FY2025 full-year result was $77.6 million, down 52.6% from the prior year.
• Cash & Equivalents rose to $144.4 million in Q1 2026, from $77.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $437.2 million in Q3 2023 to a low of $32.8 million in Q2 2025.
• A 5-year average of $181.4 million and a median of $144.4 million in 2026 frame the typical range for Cash & Equivalents.
• Peak annual rise in Cash & Equivalents reached 518.51% in 2024, while the deepest fall reached 90.2% in 2024.
• Tracing RCKT's Cash & Equivalents over 5 years: stood at $140.5 million in 2022, then slumped by 60.22% to $55.9 million in 2023, then surged by 192.71% to $163.6 million in 2024, then tumbled by 52.6% to $77.6 million in 2025, then surged by 86.18% to $144.4 million in 2026.
• Business Quant data shows RCKT's Cash & Equivalents at $144.4 million in Q1 2026, $77.6 million in Q4 2025, and $222.8 million in Q3 2025.